drugset / Trial / NCT06235229
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2023-12-26
- Primary completion
- 2026-03-02
- Completion
- 2026-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | — | Other |